fosinopril has been researched along with omapatrilat in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (18.18) | 18.2507 |
| 2000's | 9 (81.82) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Azizi, M; Guyene, TT; Mangold, B; Massien, C; Ménard, J; Vesterqvist, O | 1 |
| Azizi, M; Corvol, P; Massien, C; Michaud, A | 1 |
| Bonnet, F; Burrell, LM; Cao, Z; Cooper, ME; Gilbert, RE; Tikkanen, I | 1 |
| Burnett , JC; Chen, HH; Harty, GJ; Lainchbury, JG; Matsuda, Y | 1 |
| Aguilar-Salinas, CA; Arellano, SA; Gómez-Pérez, FJ; Guillén-Pineda, LE; Magos, GA; Rodriguez, R; Villanueva-Sanchez, O | 1 |
| Atamas, N; Dong, Y; Liao, WC; Shaffer, E; Wei, C; Zhou, H | 1 |
| Azizi, M; Bissery, A; Guyene, TT; Labatide-Alanore, A; Lamarre-Cliche, M; Ménard, J | 1 |
| Maniu, CV; Meyer, DM; Redfield, MM | 1 |
| Larouche, I; Pu, Q; Schiffrin, EL | 1 |
| Burrell, LM; Cooper, ME; Jaworski, K; Kubota, E; Mifsud, SA; Wilkinson-Berka, JL | 1 |
| Abboa-Offei, BE; Asaad, MM; Bednarz, MS; Chao, S; Cheung, HS; Cimarusti, MP; Dejneka, T; Fox, M; Mathers, PD; Misra, RN; Robl, JA; Ryono, DE; Schaeffer, TR; Seymour, AA; Simpkins, LM; Slusarchyk, WA; Smith, PL; Stevenson, J; Stratton, L; Sun, CQ; Trippodo, NC | 1 |
3 trial(s) available for fosinopril and omapatrilat
| Article | Year |
|---|---|
Pharmacodynamic effects of dual neutral endopeptidase-angiotensin-converting enzyme inhibition versus angiotensin-converting enzyme inhibition in humans.
Topics: Administration, Oral; Adult; Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atrial Natriuretic Factor; Cross-Over Studies; Double-Blind Method; Enzyme Inhibitors; Fosinopril; Humans; Male; Neprilysin; Pyridines; Reference Values; Renin; Thiazepines; Time Factors | 1999 |
In vitro and in vivo inhibition of the 2 active sites of ACE by omapatrilat, a vasopeptidase inhibitor.
Topics: Adolescent; Adult; Angiotensin-Converting Enzyme Inhibitors; Animals; Catalytic Domain; CHO Cells; Cricetinae; Cross-Over Studies; Double-Blind Method; Fosinopril; Humans; Hydrolysis; Kinetics; Male; Molecular Sequence Data; Neprilysin; Oligopeptides; Peptidyl-Dipeptidase A; Pyridines; Sodium; Substrate Specificity; Thiazepines | 2000 |
Physiologic consequences of vasopeptidase inhibition in humans: effect of sodium intake.
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Atrial Natriuretic Factor; Blood Pressure; Cross-Over Studies; Double-Blind Method; Endothelin-1; Endothelins; Fosinopril; Humans; Male; Neprilysin; Oligopeptides; Peptidyl-Dipeptidase A; Protease Inhibitors; Protein Precursors; Pyridines; Renin; Sodium, Dietary; Thiazepines; Time Factors | 2002 |
8 other study(ies) available for fosinopril and omapatrilat
| Article | Year |
|---|---|
Vasopeptidase inhibition attenuates the progression of renal injury in subtotal nephrectomized rats.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Autoradiography; Blood Pressure; Creatinine; Disease Models, Animal; Fosinopril; Glomerular Filtration Rate; Heart Failure; Hypertension, Renal; Kidney; Male; Nephrectomy; Neprilysin; Organ Size; Peptidyl-Dipeptidase A; Proteinuria; Pyridines; Rats; Rats, Sprague-Dawley; Renal Insufficiency; Renin; Thiazepines; Urea | 2001 |
Endogenous natriuretic peptides participate in renal and humoral actions of acute vasopeptidase inhibition in experimental mild heart failure.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Atrial Natriuretic Factor; Blood Pressure; Cyclic GMP; Dogs; Fosinopril; Glomerular Filtration Rate; Heart Failure; Male; Neprilysin; Polysaccharides; Protease Inhibitors; Pyridines; Receptors, Atrial Natriuretic Factor; Sodium; Thiazepines | 2001 |
Effects of omapatrilat on blood pressure and insulin sensitivity in an animal model of insulin resistance.
Topics: Animals; Antihypertensive Agents; Blood Glucose; Blood Pressure; Double-Blind Method; Fosinopril; Glucose Tolerance Test; Insulin; Insulin Resistance; Male; Models, Animal; Obesity; Pyridines; Rats; Rats, Zucker; Thiazepines; Triglycerides | 2001 |
The cardiovascular actions of omapatrilat in spontaneously hypertensive rats.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Cardiovascular Agents; Endocardium; Fosinopril; Hemodynamics; Hypertension; Hypertrophy, Left Ventricular; Male; Pyridines; Rats; Rats, Inbred SHR; Thiazepines; Ventricular Function, Left | 2001 |
Hemodynamic and humoral effects of vasopeptidase inhibition in canine hypertension.
Topics: Adrenomedullin; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Atrial Natriuretic Factor; Dogs; Fosinopril; Hemodynamics; Hypertension; Kinetics; Male; Neprilysin; Peptides; Protease Inhibitors; Pyridines; Thiazepines; Vasoconstrictor Agents | 2002 |
Effect of dual angiotensin converting enzyme/neutral endopeptidase inhibition, angiotensin converting enzyme inhibition, or AT1 antagonism on coronary microvasculature in spontaneously hypertensive rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Arterioles; Biphenyl Compounds; Blood Pressure; Capillaries; Coronary Circulation; Drug Therapy, Combination; Fosinopril; Hypertension; Irbesartan; Male; Myocytes, Cardiac; Neprilysin; Pyridines; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Tetrazoles; Thiazepines | 2003 |
Cardiorenal protective effects of vasopeptidase inhibition with omapatrilat in hypertensive transgenic (mREN-2)27 rats.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Animals, Genetically Modified; Antihypertensive Agents; Atrial Natriuretic Factor; Biomarkers; Blood Pressure; Body Weight; Cardiomegaly; Disease Models, Animal; Dose-Response Relationship, Drug; Fosinopril; Hypertension; Kidney; Male; Models, Cardiovascular; Neprilysin; Pyridines; Rats; Renin; Statistics as Topic; Survival Analysis; Systole; Thiazepines; Time Factors; Treatment Outcome | 2004 |
Dual metalloprotease inhibitors: mercaptoacetyl-based fused heterocyclic dipeptide mimetics as inhibitors of angiotensin-converting enzyme and neutral endopeptidase.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Atrial Natriuretic Factor; Cardiovascular Agents; Cyclic GMP; Enzyme Inhibitors; Heart Failure; Hypertension; Macaca fascicularis; Neprilysin; Pyridines; Rats; Renin; Sodium; Thiazepines | 1997 |